Korean J Hematol.  2011 Mar;46(1):3-5. 10.5045/kjh.2011.46.1.3.

Natural killer cell-based immunotherapy for treating cancer: will it be promising?

• Cho D
• Kim SK
• Carson WE

• KMID: 2252009
• DOI: http://doi.org/10.5045/kjh.2011.46.1.3

Abstract

No abstract available.

MeSH Terms

Immunotherapy

Figure

• 

  Fig. 1 Representative examples of combinatorial approaches of natural killer (NK) cell immunotherapy with chemotherapy, radiation, or monoclonal antibody (mAb) therapy. One approach (A) would be to combine NK cell immunotherapy with chemotherapy (e.g., bortezomib), which downregulates cell surface expression of human leukocyte antigen (HLA) class I on target cells (missing self) and enhances NK cell-mediated lysis of tumor targets. Another approach (B) is to combine NK cell therapy with radiation therapy, which is known to increase the expression of NK activating ligands (e.g., NKG2D ligands MICA and MICB) on malignant cells (induced self), thus rendering tumors more susceptible to NK cell cytotoxic activity. The third approach (C) is to combine NK cell immunotherapy with mAb therapy (e.g., the anti-HER2/neu mAb trastuzumab). NK cells express an activating Fc receptor (FcγRIIIa, CD16) that recognizes the constant region of IgG and allows them to kill antibody-coated target cells via antibody-dependentcell-mediated cytotoxicity.

Reference

1. Stern-Ginossar N, Mandelboim O. Lotze MT, Thomson AW, editors. Receptors on NK cells. Natural killer cells: basic science and clinical application. 2010. 1st ed. London, UK: Academic Press;p. 155–168.

2. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008; 9:486–494. PMID: 18425105.

3. Cooley S, Miller JS. Lotze MT, Thomson AW, editors. Clinical trials of NK cells for cancer. Natural killer cells: basic science and clinical application. 2010. 1st ed. London, UK: Academic Press;p. 555–570.

4. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010; 16:3901–3909. PMID: 20542985.

5. Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009; 8:2983–2991. PMID: 19887543.